ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.594,95
0,61%
S&P 500
5.270,45
-0,13%
Dow Jones
38.484,29
-0,52%
Euro vs US Dollar
1,08719
0,18%
Bitcoin
69.081,57
1,97%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Spruce Biosciences Inc (SPRB)

  7. Spruce Biosciences Inc (SPRB) News

SPRB

Spruce Biosciences (SPRB)

Spruce Biosciences Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:SPRB
DatumZeitQuelleÜberschriftSymbolFirma
03/06/202413h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPRBSpruce Biosciences Inc
03/06/202413h00Business WireSpruce Biosciences Presented Phase 2 POWER Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at ENDO 2024NASDAQ:SPRBSpruce Biosciences Inc
24/05/202422h29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPRBSpruce Biosciences Inc
24/05/202422h27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPRBSpruce Biosciences Inc
24/05/202422h26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPRBSpruce Biosciences Inc
24/05/202422h24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPRBSpruce Biosciences Inc
24/05/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPRBSpruce Biosciences Inc
23/05/202422h05Business WireSpruce Biosciences to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:SPRBSpruce Biosciences Inc
22/05/202422h14Business WireSpruce Biosciences Announces Poster Presentations at the 2024 Annual Meeting of the Endocrine SocietyNASDAQ:SPRBSpruce Biosciences Inc
13/05/202422h09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SPRBSpruce Biosciences Inc
13/05/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPRBSpruce Biosciences Inc
13/05/202422h01Business WireSpruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate UpdatesNASDAQ:SPRBSpruce Biosciences Inc
01/05/202422h05Business WireSpruce Biosciences to Participate in May Investor ConferencesNASDAQ:SPRBSpruce Biosciences Inc
30/04/202422h05Business WireSpruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual MeetingNASDAQ:SPRBSpruce Biosciences Inc
22/04/202422h05Business WireSpruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual MeetingNASDAQ:SPRBSpruce Biosciences Inc
13/03/202421h08Business WireSpruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate UpdatesNASDAQ:SPRBSpruce Biosciences Inc
13/03/202421h01Business WireSpruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAHNASDAQ:SPRBSpruce Biosciences Inc
07/03/202422h07Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:SPRBSpruce Biosciences Inc
06/02/202422h15Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SPRBSpruce Biosciences Inc
30/01/202422h05Business WireSpruce Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:SPRBSpruce Biosciences Inc
22/01/202414h00Business WireSpruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal HyperplasiaNASDAQ:SPRBSpruce Biosciences Inc
08/01/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPRBSpruce Biosciences Inc
05/01/202414h00Business WireSpruce Biosciences Reports Baseline Characteristics from CAHmelia-203 and CAHmelia-204 Studies in Adult Classic CAHNASDAQ:SPRBSpruce Biosciences Inc
04/01/202414h00Business WireSpruce Biosciences Provides Clinical Program Updates and Outlook for 2024NASDAQ:SPRBSpruce Biosciences Inc
03/01/202422h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPRBSpruce Biosciences Inc
19/12/202302h17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPRBSpruce Biosciences Inc
19/12/202302h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPRBSpruce Biosciences Inc
29/11/202301h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPRBSpruce Biosciences Inc
13/11/202322h22Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SPRBSpruce Biosciences Inc
13/11/202322h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPRBSpruce Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:SPRB

Kürzlich von Ihnen besucht

DBI
DAX
DAX
NYSE
JPM
JP Morgan Chase
PM
XAUUSD
Gold vs US Dollar
NYSE
MCD
McDonalds
TG
MBG
MercedesBenz
FX
EURUSD
Euro vs US Dollar
USOTC
BASFY
BASF (QX)
DBI
SDXP
SDAX
TG
RHM
Rheinmetall
TG
D7G
Nel ASA
USOTC
RHHBY
Roche (QX)
USOTC
BNPQY
BNP Paribas (QX)
NYSE
DIS
Walt Disney
TG
DTE
Deutsche Telekom
COIN
ETHUSD
Ethereum
FX
EURJPY
Euro vs Yen
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten